Inclusion criteria were: • Older than 18 years, • More than 3 months history of NP symptoms and manifestations, • 5 or more points in the Verbal Numerical Scale (VNS) for intensity, • Patient able to distinguish between nociceptive pain and NP on history, • 3 or more of the following: dysesthesia, allodynia, hypersensitivity, tingling, burning or electric-like hyperalgesia. • Exclusion criteria: • Allergy to any of the components of the preparation, • Pregnancy, • Absence of neuropathic pain manifestations, • Unable to distinguish between the symptoms of NP and nociceptive pain.
The treatment intervantion consisted of a topical Cream of 15% ketoprofen and 5-20% ketamine analgesic cream applied 3 times/day on affected area for 3 weeks.
Sukts were a Mean pain reduction on VNS: 2.48±1.77 points (p=<0.0001). This represents a 32.84% improvement which is similar to the mean improvement obtained on the PIS ( 31.04±24.06%). Both genders show significant symptom reduction (p=<0.0001).
Half of the patients (27 of 55) manifested an improvement of at least 30%.
Side effects observed were minimal: Photosensitivity reaction in two patients, and dizzyness and minor cognitive impairment in one patient.
Seven patients (12.72%) required an increase in the ketamine dose present in the preparation; to 10% in three patients, to 15% in three patients and to 20% in one patient.
By Vargas-Schaffer G. MD, Steverman A. MD Pain Centre of Hôtel-Dieu du CHUM, Montréal:
EFFECTIVENESS OF KETOPROFEN AND KETAMINE TOPICAL CREAM IN NEURO EFFECTIVENESS OF KETOPROFEN AND KETAMINE TOPICAL CREAM IN NEUROPATHIC PAIN. A PILOT STUDY PATHIC PAIN. A PILOT STUDY.
Poster presented at http://www.cliniquesdouleur.umontreal.ca/bibliotheque/publications/Cream_EN.pdf